Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicine for treating thromboangiitis obliterans, preparation method and content determination method

A technology for thromboangiitis and vasculitis, which is applied in the field of traditional Chinese medicine, can solve the problems that the main etiology of thromboangiitis obliterans is not clear, and achieve the effect of restoring vasodilation ability, stable effect, and inhibiting vascular smooth muscle hyperplasia

Active Publication Date: 2020-08-28
唐宏
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The main cause of thromboangiitis obliterans is still unclear

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine for treating thromboangiitis obliterans, preparation method and content determination method
  • Medicine for treating thromboangiitis obliterans, preparation method and content determination method
  • Medicine for treating thromboangiitis obliterans, preparation method and content determination method

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] The drug (Xuebitong) for treating thromboangiitis obliterans is made into capsules with the following raw materials in grams: Astragalus 30g, Salvia miltiorrhiza 15g, Radix paeoniae Rubra 20g, Centipede 15g, Dilong 10g, Wood beetle 15g, and steroids Rattan 20g, Tangerine 15g, Uncaria 15g.

experiment example 1

[0038] Clinical Report on Xuebitong Capsules

[0039] 1. Observation on 50 Cases of Thromboangiitis Obliterans Treated by Xuebitong Capsules

[0040]

[0041] Conclusion: According to the accumulative clinical observation of 50 patients with thromboangiitis obliterans, the cure rate is 72%, the effective rate is 92%, the effective rate is 98%, and the ineffective rate is 2%. Significant effect.

[0042] 2. Diagnostic criteria for thromboangiitis obliterans:

[0043] 1. Male, aged 20-40. 2. Symptoms of chronic limb ischemia, such as numbness, fear of cold, intermittent claudication, nutritional disorders, etc., often involving the lower limbs, but rarely upper limbs. 3. 40-60% have a history or signs of migratory thrombotic superficial veins. 4. Various examinations have proved that the arterial occlusion and stenosis of the limbs are mostly in the popliteal artery and its distal arteries (often involving small and medium arteries). 5. History of smoking or exposure to co...

experiment example 2

[0056] Xuebitong preparation method, content determination method and curative effect verification

[0057] 2.1 Experimental materials

[0058] 2.1.1 Cells and animals

[0059] Cell line: human umbilical vein endothelial cells (HUVEC).

[0060] Animals: clean grade SD rats, male, weighing 180-200g. Adaptive feeding for one week. All were purchased from Liaoning Changsheng Biotechnology Co., Ltd.

[0061] laboratory apparatus

[0062]

[0063] 2.1.3 Experimental reagents

[0064]

[0065] 2.1.4 Medicinal materials

[0066] The standards of medicinal materials in this experiment are in accordance with the items of medicinal materials in the 2015 edition of the Chinese Pharmacopoeia.

[0067] Liquid phase conditions

[0068] Astragaloside IV: InertSustain C18 column (5 μm, 4.6*250 mm) with octadecylsilane bonded silica gel as filler, acetonitrile-water (35:65) as mobile phase, evaporative light scattering detector, The flow rate was 1.0 mL / min, the column temperatu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
Login to View More

Abstract

The invention relates to the field of traditional Chinese medicines, and in particular relates to a medicine for treating thromboangiitis obliterans, a preparation method and a content determination method. The product name of the medicine is Xuebitong capsule. The medicine components are prepared from the following raw materials in parts by weight: 25-35 parts of astragalus membranaceus, 12-18 parts of salvia miltiorrhiza, 15-25 parts of radix paeoniae rubra, 12-18 parts of centipedes, 8-12 parts of earthworms, 12-18 parts of ground beeltles, 15-25 parts of Chinese starjasmine stems, 12-18 parts of exocarpium citri rubrum and 12-18 parts of uncaria. The optimal extraction process parameters of the medicine are that a 80% ethanol solution is adopted, the solid-to-liquid ratio is 1:8, extraction is carried out twice, and extraction lasts for one hour each time. The extraction process is feasible, and the effect is stable. The content of effective components is simple and easy to determine, and quality of the medicine can be objectively, truly and comprehensively monitored.

Description

technical field [0001] The invention relates to the field of traditional Chinese medicine, namely a medicine for treating thromboangiitis obliterans, a preparation method and a content determination method. Product name: Xuebitong Capsules. Background technique [0002] In the prior art, Thromboangitis obliterans (TAO), also known as Buerger's disease, is a common peripheral vascular disease. There are two factors. External factors mainly include cold and humid living environment, smoking, infection and chronic injury, etc. Internal factors mainly include autoimmune system disorder, prostatic hormone disorder and heredity. Various factors lead to endothelial dysfunction, that is, the endothelium-dependent vasodilation function is damaged, and pathogenic factors induce the release of inflammatory factors, resulting in the adhesion of immune cells and endothelial cells, and finally induce the formation of intravascular thrombosis and vasculitis. The main clinical manifestat...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/752A61P9/14G01N30/06G01N30/74G01N30/86A61K35/648A61K35/62A61K35/64
CPCA61K35/62A61K35/64A61K35/648A61K36/24A61K36/481A61K36/537A61K36/65A61K36/71A61K36/74A61K36/752A61K2236/333A61K2236/39A61P9/14G01N30/06G01N30/74G01N30/8634A61K2300/00
Inventor 唐宏
Owner 唐宏
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com